Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036327 | 1.00 | MAPT (0.47) | MAPTCTSVCTSLALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL10560974 | 0.98 | MAPT (0.46) | MAPTCTSVCTSLALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL10560963 | 0.98 | MAPT (0.46) | MAPTCTSVCTSLALDH1A1TDP1 | |
| SCHEMBL6958431 | 0.86 | SMN1; SMN2 (0.43) | MAPTALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL801045 | 0.85 | CASP1 (0.54) | MAPTALDH1A1CYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL17080674 | 0.85 | CYP1A2 (0.43) | MAPTALDH1A1CYP3A4ALOX15KMT2A | |
| SCHEMBL4067681 | 0.82 | LMNA (0.49) | MAPTALDH1A1CYP3A4KMT2AMAPK1 | |
| SCHEMBL30618280 | 0.81 | OPRK1 (0.50) | MAPTALDH1A1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL2692671 | 0.81 | OPRK1 (0.50) | MAPTALDH1A1KMT2AMAPK1SMN1; SMN2 | |
| SCHEMBL1818933 | 0.81 | MAPT (0.49) | MAPTCTSVCTSLALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813537-B | Preparation method and application of novel flunixin hapten | 深圳市绿诗源生物技术有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-116813537-A | Preparation method and application of novel flunixin hapten | 深圳市绿诗源生物技术有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4651907-A1 | DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME | Adcentrx Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4563571-A1 | PRMT5 INHIBITORS | Beijing Earthwise Technology Co., Ltd. (CN) | 2025-06-04 | — | — | EP | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119731154-A | PRMT5 inhibitors | 北京望实智慧科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-116813537-B | Preparation method and application of novel flunixin hapten | 深圳市绿诗源生物技术有限公司 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024155761-A1 | DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME | ADCENTRX THERAPEUTICS INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-5705499-A | VIRICIDES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5620974-A | ENZYME INHIBITOR, TREATS ACQUIRED IMMUNE DEFICIENCY SYNDROME(AIDS) | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0767172-A1 | 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5550122-A | INHIBIT REVERSE TRANSCRIPTASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0415303-B1 | Pyrido [2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMA (US) | 1995-12-13 | — | — | EP | disclosed |
| EP-0634413-A1 | Herbicides | RHONE POULENC AGRICULTURE LTD. (GB) | 1995-01-18 | — | — | EP | disclosed |
| US-5366972-A | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0429987-A2 | 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepines and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0415303-A2 | Pyrido [2,3-b][1,5]benzoxazepin (and thiazepin)-5(6H)-ones and -thiones and their use in the prevention or treatment of HIV infection | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | MAPT 2749/4885CTSV 1063/4885CTSL 1362/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885CTSV 1063/4885CTSL 1362/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | MAPT 4259/4885CTSV 1913/4885CTSL 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.